Scientists have refined anti-CD19 chimeric antigen receptor (CAR) T cell therapy, an investigational treatment for advanced non-Hodgkin’s lymphoma, with initial results showing significantly higher response and survival rates than the standard repertoire.
Blinatumomab, a bispecific T-cell engager (BiTE), nearly doubled overall survival (OS) and complete remission (CR) rate vs standard chemotherapy in patients with Philadelphia chromosome (Ph)-negative relapsed/refractory B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) in the phase III TOWER trial.
A large study presented at the 21st Congress of European Haematology Association (EHA) provides further evidence for the feasibility and safety of stopping tyrosine kinase inhibitor (TKI) therapy in patients with chronic myeloid leukaemia (CML) who have achieved a deep molecular response (MR).
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Pharmacist - Malaysia digital copy today!
Nonvitamin K antagonist oral anticoagulants (NOAC)-associated intracerebral haemorrhage (ICH) and vitamin K antagonists-ICH appear to have similar ICH volume, haematoma expansion, functional outcome and mortality, results of a recent meta-analysis have shown.
New drug applications approved by US FDA as of 16 - 31 May 2017 which
includes New Molecular Entities (NMEs) and new biologics. It does not
include Tentative Approvals. Supplemental approvals may have occurred
since the original approval date.